| Chia-chi Wang, DO | |
|
520 Saybrook Rd, S100, Middletown, CT 06457-4700 | |
| (860) 346-2608 | |
| (860) 347-4691 |
| Full Name | Chia-chi Wang |
|---|---|
| Gender | Female |
| Speciality | Surgical Oncology |
| Experience | 22 Years |
| Location | 520 Saybrook Rd, Middletown, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023254273 | NPI | - | NPPES |
| 03112190 | Medicaid | NY |
| Facility Name | Location | Facility Type |
|---|---|---|
| Middlesex Hospital | Middletown, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mhs Primary Care, Inc | 4082507371 | 143 |
News Archive
A Cornell study provides important new insights into a common and deadly type of gastric cancer.
Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.
Xybion Corporation, the leading provider of software, services and consulting for global corporations operating in highly regulated industries, announced today that the company will host its first annual Global User Group Conference, Xybion International Exchange, on October 21-23, 2014 in historic Philadelphia, Pennsylvania at the Sheraton Society Hill Hotel.
Surgery and radiation remove, kill, or damage cancer cells in a certain area. But chemotherapy - which uses medicines or drugs to treat cancer - can work throughout the whole body, killing cancer cells that have spread far from the original tumor.
At the start of the pandemic, many doctors on the front lines turned to Twitter and other social media platforms to find guidance and solace directly from their peers. In early 2020, information on COVID-19 had yet to be studied and published in peer-reviewed journals or printed in medical textbooks.
› Verified 9 days ago
| Entity Name | Mhs Primary Care, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740666312 PECOS PAC ID: 4082507371 Enrollment ID: O20040202000945 |
News Archive
A Cornell study provides important new insights into a common and deadly type of gastric cancer.
Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.
Xybion Corporation, the leading provider of software, services and consulting for global corporations operating in highly regulated industries, announced today that the company will host its first annual Global User Group Conference, Xybion International Exchange, on October 21-23, 2014 in historic Philadelphia, Pennsylvania at the Sheraton Society Hill Hotel.
Surgery and radiation remove, kill, or damage cancer cells in a certain area. But chemotherapy - which uses medicines or drugs to treat cancer - can work throughout the whole body, killing cancer cells that have spread far from the original tumor.
At the start of the pandemic, many doctors on the front lines turned to Twitter and other social media platforms to find guidance and solace directly from their peers. In early 2020, information on COVID-19 had yet to be studied and published in peer-reviewed journals or printed in medical textbooks.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chia-chi Wang, DO 28 Crescent St, Middletown, CT 06457-3654 Ph: (860) 358-4820 | Chia-chi Wang, DO 520 Saybrook Rd, S100, Middletown, CT 06457-4700 Ph: (860) 346-2608 |
News Archive
A Cornell study provides important new insights into a common and deadly type of gastric cancer.
Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.
Xybion Corporation, the leading provider of software, services and consulting for global corporations operating in highly regulated industries, announced today that the company will host its first annual Global User Group Conference, Xybion International Exchange, on October 21-23, 2014 in historic Philadelphia, Pennsylvania at the Sheraton Society Hill Hotel.
Surgery and radiation remove, kill, or damage cancer cells in a certain area. But chemotherapy - which uses medicines or drugs to treat cancer - can work throughout the whole body, killing cancer cells that have spread far from the original tumor.
At the start of the pandemic, many doctors on the front lines turned to Twitter and other social media platforms to find guidance and solace directly from their peers. In early 2020, information on COVID-19 had yet to be studied and published in peer-reviewed journals or printed in medical textbooks.
› Verified 9 days ago
Dr. Kertrisa R Mcwhite, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 540 Saybrook Rd Ste 100, Middletown, CT 06457 Phone: 860-358-2850 Fax: 860-358-8661 | |
James Michael Parker, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 540 Saybrook Rd Ste 100, Middletown, CT 06457 Phone: 860-358-2850 Fax: 860-358-8698 | |
Dr. Paul K. Safer, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 520 Saybrook Rd, Middletown, CT 06457 Phone: 860-346-2608 Fax: 860-347-4691 | |
Dr. Andrea Marie Malon, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 540 Saybrook Rd Ste 100, Middletown, CT 06457 Phone: 860-358-2850 Fax: 860-358-8698 | |
Dr. Matthew David Behringer, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 540 Saybrook Rd, Middletown, CT 06457 Phone: 860-358-2850 Fax: 860-358-8698 | |
Joseph A Coatti, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 400 Saybrook Rd, Suite 110, Middletown, CT 06457 Phone: 860-347-9167 Fax: 860-347-1630 |